BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31507425)

  • 1. Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation.
    Teopompi E; Risé P; Pisi R; Buccellati C; Aiello M; Pisi G; Tripodi C; Fainardi V; Clini E; Chetta A; Rovati GE; Sala A
    Front Pharmacol; 2019; 10():938. PubMed ID: 31507425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis.
    Eickmeier O; Fussbroich D; Mueller K; Serve F; Smaczny C; Zielen S; Schubert R
    PLoS One; 2017; 12(2):e0171249. PubMed ID: 28158236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.
    O'Connor MG; Thomsen K; Brown RF; Laposata M; Seegmiller A
    Prostaglandins Leukot Essent Fatty Acids; 2016 Oct; 113():46-49. PubMed ID: 27720040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites.
    Le Faouder P; Baillif V; Spreadbury I; Motta JP; Rousset P; Chêne G; Guigné C; Tercé F; Vanner S; Vergnolle N; Bertrand-Michel J; Dubourdeau M; Cenac N
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():123-33. PubMed ID: 23831705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients.
    Morin C; Cantin AM; Vézina FA; Fortin S
    Mar Drugs; 2018 May; 16(6):. PubMed ID: 29861448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proresolving Action of Docosahexaenoic Acid Monoglyceride in Lung Inflammatory Models Related to Cystic Fibrosis.
    Morin C; Cantin AM; Rousseau É; Sirois M; Sirois C; Rizcallah E; Fortin S
    Am J Respir Cell Mol Biol; 2015 Oct; 53(4):574-83. PubMed ID: 25781052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.
    Yang J; Eiserich JP; Cross CE; Morrissey BM; Hammock BD
    Free Radic Biol Med; 2012 Jul; 53(1):160-71. PubMed ID: 22580336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils.
    Lee TH; Mencia-Huerta JM; Shih C; Corey EJ; Lewis RA; Austen KF
    J Clin Invest; 1984 Dec; 74(6):1922-33. PubMed ID: 6096400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis.
    Bravo E; Napolitano M; Valentini SB; Quattrucci S
    Lipids Health Dis; 2010 Nov; 9():129. PubMed ID: 21059219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.
    Lloyd-Still JD; Powers CA; Hoffman DR; Boyd-Trull K; Lester LA; Benisek DC; Arterburn LM
    Nutrition; 2006 Jan; 22(1):36-46. PubMed ID: 16226012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis.
    Jumpsen JA; Brown NE; Thomson AB; Paul Man SF; Goh YK; Ma D; Clandinin MT
    J Cyst Fibros; 2006 May; 5(2):77-84. PubMed ID: 16507353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of DHA supplementation on oxylipin levels in plasma and immune cell stimulated blood.
    Schuchardt JP; Ostermann AI; Stork L; Fritzsch S; Kohrs H; Greupner T; Hahn A; Schebb NH
    Prostaglandins Leukot Essent Fatty Acids; 2017 Jun; 121():76-87. PubMed ID: 28651702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of arachidonic acid metabolites on the control of non-differentiated intestinal epithelial cell growth.
    Cabral M; Martín-Venegas R; Moreno JJ
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1620-8. PubMed ID: 23685077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-lipoxygenase-dependent biosynthesis of novel 20:4 n-3 metabolites with anti-inflammatory activity.
    Gagnon KJ; Lefort N; Poirier SJ; Barnett DA; Surette ME
    Prostaglandins Leukot Essent Fatty Acids; 2018 Nov; 138():38-44. PubMed ID: 30392579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and metabolism of leukotrienes in granulocytes of patients with cystic fibrosis.
    Saak A; Schönfeld W; Knöller J; Steinkamp G; von der Hardt H; König W
    Int Arch Allergy Appl Immunol; 1990; 93(2-3):227-36. PubMed ID: 1965982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners.
    Archambault AS; Brassard J; Bernatchez É; Martin C; Di Marzo V; Laviolette M; Boulet LP; Blanchet MR; Flamand N
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA.
    Al-Turkmani MR; Andersson C; Alturkmani R; Katrangi W; Cluette-Brown JE; Freedman SD; Laposata M
    J Lipid Res; 2008 Sep; 49(9):1946-54. PubMed ID: 18480495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide.
    Guilbault C; Wojewodka G; Saeed Z; Hajduch M; Matouk E; De Sanctis JB; Radzioch D
    Am J Respir Cell Mol Biol; 2009 Jul; 41(1):100-6. PubMed ID: 19059886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic intracutaneous administration of arachidonic acid and its metabolites. Induction of leukocytoclastic vasculitis by leukotriene B4 and 12-hydroxyeicosatetraenoic acid and its prevention by prostaglandin E2.
    Ruzicka T; Burg G
    J Invest Dermatol; 1987 Feb; 88(2):120-3. PubMed ID: 3027188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the relationship between 5-lipoxygenase product generation and the secretion of preformed mediators from mouse bone marrow-derived mast cells.
    Razin E; Romeo LC; Krilis S; Liu FT; Lewis RA; Corey EJ; Austen KF
    J Immunol; 1984 Aug; 133(2):938-45. PubMed ID: 6330206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.